
Concept Protocols
For study leads and sponsors: how to agree a study’s design in a short concept before the full protocol is written, with a practical workflow and the questions to ask.
Download the free guideClinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipInsider’s Insights / Clinical Trial Protocols
The protocol is where a trial’s idea is made real: it tells ethics committees who will be recruited, regulators how evidence will be generated and sites what to do. This guide covers study design, protocol writing and regulatory requirements, and shows where ICH M11 helps, and where it does not.
Six things you will be able to do after reading this guide.
Use a study design workshop and a concept protocol to settle the science before writing starts.
Population, treatment, variable, intercurrent events and summary measure, agreed up front.
Treat the schedule of activities as the central reference and test the rest against it.
Why 45% of substantial amendments are avoidable, and how to keep yours out of that group.
The template, the technical specification and the structured, digital protocol behind them.
What the EU, UK and US actually require, and where good practice takes over.
Three quick questions taken from the guide. Test what you already know.
0of 3 correct so far
Question 1 of 3
In a Tufts study, what share of protocols had at least one substantial amendment?
Question 2 of 3
What was the median direct cost of implementing a substantial amendment in a phase III study?
Question 3 of 3
Who classified a larger share of procedures as non-core: sponsors or FDA reviewers?
The guide covers each of these in depth, from design to regulatory submission.
Download the free guideA few of the 19 pages, so you know exactly what you are getting.
It depends on the region. In the EU, the guideline came into effect on 11 June 2026; in the US it is non-binding FDA guidance. We advise treating M11 as the default for new protocols, documenting any deliberate departure from the template, and confirming regional expectations before the first filing.
Start with the next new study. Converting a running protocol rarely pays for itself, and an amendment made only to change the layout creates work for sites and committees. Keep a mapping document and use M11 headings at natural boundaries, such as the next protocol in a series.
Start with what the study must decide. For every procedure, name the decision it informs, who will use the data and when. Where the answer is vague, the procedure is a candidate for removal or an optional substudy. Ask sites and participants to read the draft.
More than you may think for the mechanical parts, such as consistency checks and carrying the schedule of activities between documents, and less than you may hope for the judgement. Design rationale, risk decisions and the benefit-risk narrative should stay human work, because accountability stays with the sponsor and investigator.
Agree the study’s design in a short concept before the full protocol is written.
Protocols, reports, manuscripts and submission documents written to agency and journal standards.
Study planning and delivery from concept to close-out, with protocols that work in practice.